Denmark
IO Biotech is a clinical-stage biopharmaceutical company headquartered in Copenhagen, Denmark. The company's mission revolves around pioneering a first-in-class investigational dual-action immune-modulating cancer vaccine, with the ultimate goal of serving as the backbone of combination therapy for individuals battling cancer. Their T-win® vaccine platform is specifically targeting the tumor microenvironment (TME) and aims to activate T cells against tumor cells, as well as the most crucial immune-suppressive cells within the TME.
IO Biotech has made significant progress in advancing compounds to the clinic, with their most advanced program, IO102-IO103, currently in Phase 3 development. Additionally, the company has two lead immune modulating anti-cancer therapies targeting IDO and PD-L1 in clinical development, along with several compounds finalizing the preclinical phase.
Established in 2014, IO Biotech boasts an experienced management team within the immuno-oncology field and a world-class advisory board. The company recently secured a Post-IPO Equity investment on 07 August 2023 as a testament to investor confidence in their endeavors.
With a focus on the biotechnology and health care industries, IO Biotech is well-positioned to drive innovation in the fight against cancer, embodying the ethos of their slogan: "Break Boundaries. Ignite Change."
